Literature DB >> 16940309

VEGF polymorphisms are associated with neovascular age-related macular degeneration.

Amanda J Churchill1, James G Carter, Helen C Lovell, Conor Ramsden, Steven J Turner, Anna Yeung, Julia Escardo, Denize Atan.   

Abstract

Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. Linkage has been shown to the vascular endothelial growth factor (VEGF) gene and ocular levels of VEGF are raised in individuals with the neovascular form of disease. To examine the role of VEGF further, we conducted a case-control study where 45 individuals with neovascular AMD and 94 age-matched controls were genotyped for 14 single nucleotide polymorphisms (SNPs) in the VEGF promoter and gene. The single SNP +674 CC genotype was significantly associated with AMD (OR=2.40, 95%CI 1.09-5.26, P=0.027). Haplotype analysis of SNPs +674, +4618, +5092, +9162 and +9512 revealed that CTCCT and TCACC were associated with AMD (OR=15.77, 95% CI 1.91-130.24, P=0.0161 and OR=9.95, 95%CI 3.22-30.74, P=0.000053, respectively). The haplotype TCACT was associated with the control group (P=0.0001832). Furthermore, haplotype analysis of promoter SNPs revealed that possession of the -460T, -417T, -172C, -165C, -160C, -152G, -141A, -116A, +405C haplotype was strongly associated with AMD (OR=18.24, 95%CI 2.25-148.25, P=0.0074). This is the most extensive analysis of the VEGF gene in AMD, demonstrating a clear association with the exudative form of disease, thereby creating the possibility for predictive testing. Smoking, high fat intake and hypertension are negative environmental risk factors in AMD, whereas increased consumption of dietary antioxidants can have a protective effect. Identification of those at risk in the population would allow individual counselling with lifestyle advice to reduce the risks of blindness. (Genbank accession nos M63971 and AF437895).

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16940309     DOI: 10.1093/hmg/ddl238

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  72 in total

1.  Copy number variations in candidate genes in neovascular age-related macular degeneration.

Authors:  Melissa M Liu; Elvira Agrón; Emily Chew; Catherine Meyerle; Frederick L Ferris; Chi-Chao Chan; Jingsheng Tuo
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-16       Impact factor: 4.799

Review 2.  Age-related macular degeneration: genetic and environmental factors of disease.

Authors:  Yuhong Chen; Matthew Bedell; Kang Zhang
Journal:  Mol Interv       Date:  2010-10

3.  Pooled-analysis of the associations between three polymorphisms in the VEGF gene and age-related macular degeneration.

Authors:  Yan Lu; Yuhua Shi; Chunyan Xue; Jie Yin; Zhenping Huang
Journal:  Mol Biol Rep       Date:  2012-02-04       Impact factor: 2.316

4.  Polymorphisms in the VEGF-A in polypoidal choroidal vasculopathy in a Korean population.

Authors:  Dong Ho Park; In Taek Kim
Journal:  Jpn J Ophthalmol       Date:  2012-02-04       Impact factor: 2.447

5.  Roles of three common VEGF polymorphisms in the risk of age-related macular degeneration.

Authors:  Yuqing Liu; Siqing Hou; Weihua Lang; Dongshu Dai; Zhixue Wang; Xiangning Ji; Kun Li; Xi Zhang; Yuanyuan Zou; Jingxian Wang
Journal:  Genet Test Mol Biomarkers       Date:  2014-04

Review 6.  LOC387715/HTRA1 gene polymorphisms and susceptibility to age-related macular degeneration: A HuGE review and meta-analysis.

Authors:  Yu Tong; Jing Liao; Yuan Zhang; Jing Zhou; Hengyu Zhang; Meng Mao
Journal:  Mol Vis       Date:  2010-10-05       Impact factor: 2.367

Review 7.  Genetic susceptibility to retinopathy of prematurity: the evidence from clinical and experimental animal studies.

Authors:  Gerd Holmström; Peter van Wijngaarden; Douglas J Coster; Keryn A Williams
Journal:  Br J Ophthalmol       Date:  2007-12       Impact factor: 4.638

8.  Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.

Authors:  Fernando Cruz-Gonzalez; Lucía Cabrillo-Estévez; Gloria López-Valverde; Clara Cieza-Borrella; Emiliano Hernández-Galilea; Rogelio González-Sarmiento
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-13       Impact factor: 3.117

Review 9.  Next-generation therapeutic solutions for age-related macular degeneration.

Authors:  Khrishen Cunnusamy; Rafael Ufret-Vincenty; Shusheng Wang
Journal:  Pharm Pat Anal       Date:  2012-05

10.  FLT1 genetic variation predisposes to neovascular AMD in ethnically diverse populations and alters systemic FLT1 expression.

Authors:  Leah A Owen; Margaux A Morrison; Jeeyun Ahn; Se Joon Woo; Hajime Sato; Rosann Robinson; Denise J Morgan; Fani Zacharaki; Marina Simeonova; Hironori Uehara; Usha Chakravarthy; Ruth E Hogg; Balamurali K Ambati; Maria Kotoula; Wolfgang Baehr; Neena B Haider; Giuliana Silvestri; Joan W Miller; Evangelia E Tsironi; Lindsay A Farrer; Ivana K Kim; Kyu Hyung Park; Margaret M DeAngelis
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-05-08       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.